201 related articles for article (PubMed ID: 10702559)
1. In vitro activity of gemifloxacin (SB 265805; LB20304a) against human mycoplasmas.
Hannan PC; Woodnutt G
J Antimicrob Chemother; 2000 Mar; 45(3):367-9. PubMed ID: 10702559
[TBL] [Abstract][Full Text] [Related]
2. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp.
Duffy LB; Crabb D; Searcey K; Kempf MC
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():29-33. PubMed ID: 10824029
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae.
Waites KB; Crabb DM; Duffy LB
Int J Antimicrob Agents; 2003 Jun; 21(6):574-7. PubMed ID: 12791472
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized.
Bebear CM; Renaudin H; Charron A; Gruson D; Lefrancois M; Bebear C
Antimicrob Agents Chemother; 2000 Sep; 44(9):2557-60. PubMed ID: 10952617
[TBL] [Abstract][Full Text] [Related]
5. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Renaudin H; Bébéar C
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Bébéar CM; Renaudin H; Schaeverbeke T; Leblanc F; Bébéar C
J Antimicrob Chemother; 1999 May; 43(5):711-4. PubMed ID: 10382895
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
Pereyre S; Renaudin H; Bébéar C; Bébéar CM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3165-8. PubMed ID: 15273141
[TBL] [Abstract][Full Text] [Related]
9. Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years.
De Francesco MA; Caracciolo S; Bonfanti C; Manca N
J Infect Chemother; 2013 Aug; 19(4):621-7. PubMed ID: 23192735
[TBL] [Abstract][Full Text] [Related]
10. In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
Cohen MA; Huband MD
J Antimicrob Chemother; 1997 Aug; 40(2):308-9. PubMed ID: 9302005
[No Abstract] [Full Text] [Related]
11. Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in genital samples collected over 6 years at a Serbian university hospital.
Skiljevic D; Mirkov D; Vukicevic J
Indian J Dermatol Venereol Leprol; 2016; 82(1):37-41. PubMed ID: 26728808
[TBL] [Abstract][Full Text] [Related]
12. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.
Furneri PM; Bisignano G; Cerniglia G; Nicoletti G; Cesana M; Tempera G
Antimicrob Agents Chemother; 1994 Nov; 38(11):2651-4. PubMed ID: 7872762
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis.
Ullmann U; Schubert S; Krausse R
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():33-6. PubMed ID: 10404335
[TBL] [Abstract][Full Text] [Related]
14. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
Dubois J; St-Pierre C
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():41-6. PubMed ID: 10824031
[TBL] [Abstract][Full Text] [Related]
16. Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against
Valentine-King MA; Cisneros K; James MO; Huigens RW; Brown MB
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642935
[TBL] [Abstract][Full Text] [Related]
17. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis.
Bébéar CM; de Barbeyrac B; Pereyre S; Renaudin H; Clerc M; Bébéar C
Clin Microbiol Infect; 2008 Aug; 14(8):801-5. PubMed ID: 18727805
[TBL] [Abstract][Full Text] [Related]
18.
Waites KB; Crabb DM; Xiao L; Duffy LB; Leal SM
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513794
[TBL] [Abstract][Full Text] [Related]
19. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
Wise R; Andrews JM
J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
Waites KB; Cassell GH; Canupp KC; Fernandes PB
Antimicrob Agents Chemother; 1988 Oct; 32(10):1500-2. PubMed ID: 2973283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
